The gastrointestinal disorder drug developer was co-founded by researchers from Stanford University.

Mozart Therapeutics, US-based autoimmune and inflammatory disease drug developer co-founded by Stanford University researchers, publicly launched yesterday with $55m in series A funding led by Arch Venture Partners.

Pharmaceutical producers Bayer, Eli Lilly and Merck & Co all took part, as did Sofinnova Partners and Altitude Life Science Ventures as well as Alexandria Venture Investments, participating on behalf of life sciences real estate investment trust Alexandria Real Estate Equities.

Merck and Bayer participated in the round through MRL Ventures Fund…